Loading...
Early change in glucose metabolic rate measured using FDG-PET in patients with high-grade glioma predicts response to temozolomide but not temozolomide plus radiotherapy.
Charnley, Natalie West, Catharine M L Barnett, C Brock, Cathryn S Bydder, Graeme M Glaser, Mark Newlands, Edward S Swindell, Ric Matthews, Julian C Price, Patricia M
Charnley, Natalie
West, Catharine M L
Barnett, C
Brock, Cathryn S
Bydder, Graeme M
Glaser, Mark
Newlands, Edward S
Swindell, Ric
Matthews, Julian C
Price, Patricia M
Citations
Altmetric:
Abstract
PURPOSE: To compare the ability of positron emission tomography (PET) to predict response to temozolomide vs. temozolomide plus radiotherapy. METHODS AND MATERIALS: Nineteen patients with high-grade glioma (HGG) were studied. Patients with recurrent glioma received temozolomide 75 mg/m2 daily for 7 weeks (n=8). Newly diagnosed patients received temozolomide 75 mg/m2 daily plus radiotherapy 60 Gy/30 fractions over 6 weeks, followed by six cycles of adjuvant temozolomide 200 mg/m2/day (Days 1-5 q28) starting 1 month after radiotherapy (n=11). [18F]Fluorodeoxyglucose ([18F]FDG) PET scan and magnetic resonance imaging (MRI) were performed at baseline, and 7 and 19 weeks after initiation of temozolomide administration. Changes in glucose metabolic rate (MRGlu) and MRI response were correlated with patient survival. RESULTS: In the temozolomide-alone group, patients who survived>26 vs. or=25%, survived longer than nonresponders with mean survival times of 75 weeks (95% CI, 34-115 vs. 20 weeks (95% CI, 14-26) (p=0.0067). In the small group of patients studied, there was no relationship between MRI response and survival (p=0.52). For patients receiving temozolomide plus radiotherapy, there was no difference in survival between PET responders and nonresponders (p=0.32). CONCLUSIONS: Early changes in MRGlu predict response to temozolomide, but not temozolomide plus radiotherapy.
Description
Date
2006-10-01
Publisher
Collections
Keywords
Brain Cancer
Cancer Recurrence
Cancer Recurrence
Type
Article
Citation
Early change in glucose metabolic rate measured using FDG-PET in patients with high-grade glioma predicts response to temozolomide but not temozolomide plus radiotherapy. 2006, 66 (2):331-8 Int. J. Radiat. Oncol. Biol. Phys.